Otrixell Biotechnology (Suzhou) Co., Ltd – Trademark Portfolio

Entity Type: 99

Otrixell Biotechnology (Suzhou) Co., Ltd holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include HYDRIXELL. The owner is based in Suzhou High-tech Zone.

Room 101, 107, Building 2, No. 168, Majian Road,

Suzhou High-tech Zone 215129 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

HYDRIXELL
HYDRIXELL
Registered 2025

Trademark Classifications

Otrixell Biotechnology (Suzhou) Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Otrixell Biotechnology (Suzhou) Co., Ltd have?

Otrixell Biotechnology (Suzhou) Co., Ltd has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Otrixell Biotechnology (Suzhou) Co., Ltd file in?

Otrixell Biotechnology (Suzhou) Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 1 (Chemicals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are Otrixell Biotechnology (Suzhou) Co., Ltd's most well-known trademarks?

Otrixell Biotechnology (Suzhou) Co., Ltd's registered trademark portfolio includes well-known marks such as HYDRIXELL. These are among 1 currently registered trademark in the portfolio.

What is Otrixell Biotechnology (Suzhou) Co., Ltd's trademark registration success rate?

Otrixell Biotechnology (Suzhou) Co., Ltd has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.